Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Cancer Res. 2016 Dec 28;15(3):328–339. doi: 10.1158/1541-7786.MCR-16-0257-T

Figure 4.

Figure 4

Differential effects of cisplatin, DAP and Oxaliplatin on p53, MDM2 and MDM4 in resistant cells. (A) A2780, 2780CP/Cl-16 and 2780CP/Cl-24 cells were treated with cisplatin, DAP and oxaliplatin for 24 hours, harvested and then subjected to Western blot analysis using the indicated antibodies. (B) A2780 cells transfected with control-siRNA or MDM2-siRNA were treated with cisplatin, DAP or oxaliplatin for 24 hours, harvested and lysates prepared for Western blot analysis using the indicated antibodies. (C) A2780, 2780CP/Cl-16 and 2780CP/Cl-24 cells treated with cisplatin, DAP and oxaliplatin for 18 hours and then exposed to MG132 for another 6 hours. Cells were then harvested and lysates prepared and immunoprecipitated with the p53 antibody (FL-393). The proteins were resolved by SDS-PAGE and immunoblotted with the indicated antibodies (DO-7 for p53). Whole cell lysates were also similarly resolved and are represented as “input.”